Alvotech stock edges lower as biosimilar specialist holds USD 1.31 billion market cap

Alvotech stock is trading modestly lower around USD 5.35, while the Iceland based biosimilar specialist maintains a market capitalization of about USD 1.31 billion and remains a niche peer to larger pharma names such as Teva Pharmaceutical Industries.

Alvotech stock (ISIN LU2557688560) closed at 5.35 USD on Nasdaq as of September 3, 2026, a decline of 0.03 USD or 0.56% on the day according to market data compiled by Yahoo Finance. As of August 2026, the company is valued at about 1.31 billion USD in market capitalization, based on a share price around 3.88 USD reported by CompaniesMarketCap, underscoring the companys position as a mid cap player in the global biosimilars market.

Market data and peer context

The latest available quote for Alvotech stock at 5.35 USD as of September 3, 2026 places the shares notably above the 3.88 USD level used by CompaniesMarketCap to calculate the 1.31 billion USD valuation as of August 2026, implying that the current market capitalization is likely somewhat higher than that earlier snapshot while remaining in the same broad range of around 1.3 billion USD according to the two datasets. For retail investors, this comparison shows that the stock has appreciated by roughly 1.47 USD from the reference price used in the August valuation to the closing price reported at the start of September 2026, a gain of about 37.9% over that period in pure price terms.

While Alvotech focuses specifically on biosimilar development and manufacturing, larger diversified pharmaceutical peers illustrate the wider sector backdrop. Teva Pharmaceutical Industries American Depositary Receipts recently traded at 36.47 USD on the New York Stock Exchange as of September 3, 2026, according to a quote page on MarketWatch, showing how significantly larger incumbents in generic and specialty medicines carry much higher absolute share prices and market capitalizations than Alvotech. For investors evaluating Alvotech, this contrast highlights that the company remains a smaller, more focused biosimilar pure play compared with such multi segment peers.

Analyst style signals and valuation perspective

Beyond raw price movements, quantitative assessments give an additional angle on how Alvotech stock is currently perceived. An AI driven comparison between Alvotech and GE HealthCare compiled by the analytics platform Danelfin indicates an implied price target of 5.34 USD for Alvotech, with a high forecast of 7.01 USD and a low forecast of 3.47 USD, summarizing a range of model based scenarios for the shares and positioning the current 5.35 USD closing price very close to that central target level as of early September 2026. The fact that the latest quote stands just above the algorithmic target can be read as a signal that the market has already moved toward the level suggested by such quantitative tools, while leaving room for potential upside or downside within the projected interval.

Given a market capitalization near 1.31 billion USD as of August 2026 and a share price that has risen from around 3.88 USD to 5.35 USD within roughly one month, investors can infer a tightening valuation band in which expectations for Alvotechs biosimilar pipeline and manufacturing platform are increasingly reflected in the stock price. The comparison versus the AI target range also underscores that the shares currently trade within the models corridor rather than at a deep discount or extreme premium, suggesting a relatively balanced risk reward profile in the absence of sharp near term catalysts.

Biosimilar portfolio as growth driver

Alvotech, headquartered in Reykjavik, focuses on developing and producing biosimilar medicines, which are highly similar versions of already approved biological drugs used in therapy areas such as autoimmune diseases, oncology and other chronic conditions. While the latest quarter or fiscal year figures are not explicitly detailed in the day filtered search results, the companys strategy centers on building a portfolio of biosimilars to major reference products, thereby targeting both volume growth and margin expansion as healthcare systems and payers increasingly favor cost efficient alternatives to originator biologics.

Biosimilars can offer price reductions versus reference biologic drugs while maintaining comparable efficacy and safety profiles, making them an important lever for containing healthcare spending. For Alvotech, each successfully launched biosimilar represents a potential multi year revenue stream tied to the underlying reference products market size. The companys manufacturing capabilities and quality track record are therefore key to capturing share in tenders and reimbursement decisions, especially in Europe and North America where biosimilar adoption is most advanced.

Stock positioning and investor takeaways

With Alvotech stock at 5.35 USD as of September 3, 2026 and a market capitalization of about 1.31 billion USD as of August 2026, the shares currently sit in a valuation zone that reflects both the risks and opportunities of a focused biosimilar specialist. The roughly 37.9% increase from the 3.88 USD level used in the August market cap snapshot to the early September closing price shows that the market has recently repriced the stock, although the day to day move on September 3, 2026 itself was a modest decline of 0.56%.

For investors, this constellation means that short term price volatility is likely to be driven by news on regulatory approvals, launch timings, manufacturing performance and partnership structures rather than broad sector trends alone. The AI based target of 5.34 USD sits almost exactly at the current price, suggesting that quantitative models see Alvotech as fairly valued in the near term, while the wider forecast band between 3.47 USD and 7.01 USD highlights the range of possible outcomes depending on how individual biosimilar projects progress.

Alvotech key data

• Company: Alvotech S.A.
• ISIN: LU2557688560
• Ticker: ALVO
• Trading venue: Nasdaq (USA)
• Price (as of September 3, 2026): 5.35 USD
• Market capitalization: 1,310,000,000 USD (as of August 2026)
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: not part of major blue chip indices